| 000 -LEADER |
|---|
| fixed length control field |
02283nam a22001577a 4500 |
| 082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
610 |
| 100 ## - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Hadiqa Shahid |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Cinnamon-derived Carbon Dots as Therapeutic Intervention for Cognitive Impairment and Neuropathy Associated With Diabetes / |
| Statement of responsibility, etc. |
Shahid, Hadiqa |
| 264 ## - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
Islamabad : |
| Name of producer, publisher, distributor, manufacturer |
SMME- NUST; |
| Date of production, publication, distribution, manufacture, or copyright notice |
2025. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
151p. |
| Other physical details |
Soft Copy |
| Dimensions |
30cm |
| 500 ## - GENERAL NOTE |
|---|
| General note |
Diabetes mellitus, a chronic metabolic disorder affecting over 589 million adults globally,<br/>induces diabetes-associated cognitive impairment and peripheral neuropathy through<br/>sustained hyperglycemia, oxidative stress, neuroinflammation, and blood-brain barrier<br/>dysfunction. Existing therapies inadequately target both central and peripheral neural<br/>damage due to poor blood-brain barrier penetration. This study developed cinnamon barkderived carbon nanodots (CIN-CNDs) conjugated with chenodeoxycholic acid (CINCDCA) via green hydrothermal synthesis as a novel nanotherapeutic for diabetesassociated complications. Characterization using UV-Visible spectroscopy, Fourier<br/>Transform Infrared spectroscopy (FTIR), Atomic Force Microscopy (AFM), and Scanning<br/>Electron Microscopy (SEM) confirmed nanoscale particle formation (average 4.4 nm),<br/>successful functionalization, and surface morphology suitable for biomedical<br/>applications. Physicochemical testing demonstrated excellent hemocompatibility (<5%<br/>hemolysis), high drug loading efficiency (85 ± 3%), pH-stable hydrolytic stability across<br/>physiological ranges, and controlled sustained release profile over 72 hours. In<br/>streptozotocin-induced diabetic mice, CIN-CDCA nanoconjugates (10 mg/kg, i.p., 1, 4, 14<br/>days) showed significant improvements across comprehensive neuropathic pain<br/>assessments (cold allodynia, hot plate, paw pressure, tail immersion; all p<0.01) and<br/>cognitive function tests (Morris water maze, Y-maze, novel object recognition, open<br/>field).CIN-CDCA nanoconjugates demonstrate biocompatibility, targeted delivery, and<br/>disease-modifying efficacy for diabetes-associated neural complications, warranting<br/>clinical translation. |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
MS Biomedical Sciences (BMS) |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Supervisor : Dr. Aneeqa Noor |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="http://10.250.8.41:8080/xmlui/handle/123456789/57138">http://10.250.8.41:8080/xmlui/handle/123456789/57138</a> |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
|
| Koha item type |
Thesis |
